The US FDA on 10 June authorized use of Illumina’s COVIDSeq next generation sequencing diagnostic test to detect the SARS-CoV-2 virus and figure out if it’s mutating. The agency has high hopes this first-of-its-kind test will give researchers a better picture in the ongoing global fight against the COVID-19 pandemic.
Illumina Inc.'s COVIDSeq is the first next-generation sequencing (NGS) diagnostic test to be given emergency use authorization by the Food and Drug Administration. The head of the US agency says the test will allow physicians to diagnose whether a patient has the SARS-CoV-2 virus and let researchers track whether it’s mutating.
The FDA said on 10 June it had granted authorization for the COVIDSeq diagnostic test as the first of its...
Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.
A surgeon at Ochsner Health in New Orleans was able to successfully remove a rare and dangerous tumor from a patient’s spine using cutting-edge technology that would have otherwise made the procedure too risky.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
